Biopredic International supplies tissues of human and animal origin, cells, fractions and reagents such as hepatocytes and other liver specialties, skin products, blood products and other biological fluids, non-standard human and animal tissues. Its reagents are used for in-vitro testing in the pharmaceutical, cosmetic and chemical industries. Biopredic international holds a portfolio of patents and licenses, including that concerning the human hepatic stem cell line HepaRG®.
Cellenion, a Cellink group company, provides solutions and technologies for controlled cell dispensing with applications in the areas of bioprinting and single-cell isolation.
CTRS, Cell Therapies Research & Services is a French pharmaceutical company with a strong international dimension. The company’s head office is in Boulogne-Billancourt, in the western suburbs of Paris.The company is particularly involved in the field of rare diseases and ultra-rare diseases.
Created in 2017, CYPRIO is founded on ten years of research in the fields of physicochemistry, liver biology and drug screening. Cypriois the holder of a unique technology (BioPearl) for fabrication of spheroids that are physiologically more relevant than traditional monolayer models and are compatible with high throughput screening applications. Its first product, HepatoPearl, has been validated as a beneficial in vitro liver model for different applications from drug-drug interaction screening, chronic toxicity, and metabolism of low clearance compounds to disease modelling.
Eukarÿs’s history is closely tied to the C3P3 technology – the first ever non-viral artificial eukaryotic expression system that it developed from scratch.
C3P3 autonomously synthesizes the messenger RNA (s) of interest (mRNA) in the cytoplasm of the host cell in a high-throughput and efficient manner, allowing high expression of the target proteins.C3P3 stands for “chimeric cytoplasmic capping prone phage polymerase”.
The development of the first generation of C3P3 was completed by the end of 2016 with good performances. Eukarÿs is currently finalizing the third generation of its C3P3 system with much greater complexity and performances than the initial prototype. Besides its therapeutic development, Eukarÿs develops tools for the bioproduction of viruses and proteins.
Flash Therapeutics is a gene therapy company developing gene and cell-based therapies by leveraging its proprietary lentiviral delivery platform. Its major asset is a game-changing RNA delivery technology named LentiFlash with the goal ofconducting stand-alone and partnered programs for blood and immune diseases.
Fluigent is an international company which develops, manufactures and supports the most advanced microfluidic systems available. For application with droplets, cell biology, particle studies, or in other research areas, Fluigent has the expertise and knowledge to provide the most cost effective and technically advanced solutions to fluid control needs.
GoLiver Therapeutics is a spin-off of Inserm and the Nantes University specializing in the development of Advanced Therapy Medicinal Products to address an urgent unmet medical need in transplantation. GoLiver Therapeutics aims to become a world leader in regenerative medicine by treating liver diseases without a transplant using differentiated pluripotent stem cells. The company was created in 2017.
Guerbet is a French pharmaceutical group that has been supporting healthcare professionals specialized in diagnostic and interventional imaging since 1926. Guerbet develops and markets contrast media, delivery systems, medical devices, and related solutions adapted to their needs.
ScreenCell was founded with the objective of designing and producing a simple but revolutionary technology allowing the fast and effective isolating of rare circulating cells yielding free of any bias circulating tumor cellspopulation amenable to better cellular and molecular characterization important in cancer monitoring. This technology also contributes to the development of a new non-invasive approach to prenatal diagnosis. ScreenCell designed a full range of devices compatible with existing invitrodiagnostics assays and platforms, with no need for any interface development.
Terumo Europe is a core player in the EMEA healthcare market by providing best in class quality products and services.Terumo Europe are a strong actor of the Japan-based Terumo Corporation by contributing to innovation and sustainable growth. It conducts business locally while pursuing a unified EMEA strategy.
Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long-term expression.
Hépatinov develops innovative therapeutic and diagnostic approaches for hepatic pathologies
